Vector Vitale is developing a breakthrough class of therapeutic molecules that correct the structure of biomolecules, including amino acids, polypeptides, and proteins, and can be re-dosed to achieve a sustainable effect against degenerative diseases, with applications in medicine, defense, space, and related industries.
Looking for a particular Vector Vitale employee's phone or email?
The Vector Vitale annual revenue was $3 million in 2026.
Peter Novak is the Principal CEO of Vector Vitale.
1 people are employed at Vector Vitale.
Vector Vitale is based in Miami, Florida.
The NAICS codes for Vector Vitale are [31, 312, 3122, 33, 325, 32].
The SIC codes for Vector Vitale are [21, 283, 28, 20].